Filtered By:
Therapy: Hormone Replacement Therapy
This page shows you your search results in order of relevance. This is page number 3.
Order by Relevance | Date
Total 161 results found since Jan 2013.
HRT optimization, using transdermal estradiol plus micronized progesterone, a safer HRT.
Abstract
ABSTRACT Hormone replacement therapy (HRT) remains the gold standard for treatment of climacteric symptoms in menopausal women; it is relatively safe in healthy subjects for at least 5 years, provided it had been initiated before the age of 60 years and/or within 10 years from menopause. Estrogen probably adds some cardioprotection, that can, however, be obscured by progestogens, especially medroxyprogesterone acetate (MPA). Oral HRT is associated with an increased risk of venous thromboembolism (VTE), gallbladder disease and possibly stroke. The increased occurrence of all these events can be prevented b...
Source: Climacteric - July 19, 2013 Category: Geriatrics Authors: L'hermite M Tags: Climacteric Source Type: research
Plasma Levels of the Proinflammatory Chitin-Binding Glycoprotein YKL-40, Variation in the Chitinase 3-Like 1 Gene (CHI3L1), and Incident Cardiovascular Events Epidemiology
Conclusions
Among initially healthy U.S. women, plasma levels of the proinflammatory chitenase-like protein, YKL-40, were influenced by environmental as well as genetic factors and predicted incident thromboembolic stroke, but not MI, a differential effect consistent with limited previous data.
Source: JAHA:Journal of the American Heart Association - June 23, 2014 Category: Cardiology Authors: Ridker, P. M., Chasman, D. I., Rose, L., Loscalzo, J., Elias, J. A. Tags: Epidemiology Source Type: research
Can HRT in early menopause cut heart disease risk?
ConclusionThis double-blind RCT found that women taking HRT less than six years after the menopause had slower artery wall thickening than those taking a placebo. This represented the main measure of atherosclerosis progression tested; other measures showed no difference, so the results were not as conclusive as they could have been. Women taking HRT 10 or more years after menopause also showed no difference in atherosclerosis progression compared with a placebo, further complicating the picture.An important limitation of this study is the lack of a patient relevant endpoint, such as cardiovascular events or mortality. Pre...
Source: NHS News Feed - April 1, 2016 Category: Consumer Health News Tags: Heart/lungs Medication Source Type: news
Vascular risk factors for male and female urgency urinary incontinence at age 68 years from a British birth cohort study
ConclusionMultifactorial mechanisms lead to UUI and vascular risk factors may contribute to the pathogenesis of bladder overactivity in addition to higher BMI. Severe UUI appears to be a distinct presentation with more specific contributory mechanisms than milder UUI.
Source: BJU International - March 7, 2018 Category: Urology & Nephrology Authors: Alex Tsui, Diana Kuh, Linda Cardozo, Daniel Davis Tags: Original Article Source Type: research
Sex and Gender Considerations in Episodic Migraine
AbstractPurpose of ReviewWe seek to update readers on recent advances in our understanding of sex and gender in episodic migraine with a two part series. In part 1, we examine migraine epidemiology in the context of sex and gender, differences in symptomatology, and the influence of sex hormones on migraine pathophysiology (including CGRP). In part 2, we focus on practical clinical considerations for sex and gender in episodic migraine by addressing menstrual migraine and the controversial topic of hormone-containing therapies. We make note of data applicable to gender minority populations, when available, and summarize kn...
Source: Current Pain and Headache Reports - June 9, 2022 Category: Neurology Source Type: research
In recently postmenopausal women, HRT reduced a composite of death, MI, or heart failure at 10 years.
CONCLUSION In recently postmenopausal women, hormone replacement therapy reduced a composite of death, myocardial infarction, or heart failure after 10 years of therapy and an additional 6 years of follow-up.Hormone replacement therapy (HRT) vs no HRT in recently postmenopausal women†OutcomesEvent ratesAfter 10 y of therapyHRTNo HRTRRR (95% CI)NNT (CI)Death, MI, or HF‡3.2%6.5%50% (11 to 72)31 (22 to 144)At 16 yDeath, MI, or HF§6.6%11%37% (4 to 59)26 (17 to 251)†HF = heart failure; MI = myocardial infarction; other abbreviations defined in Glossary. RRR, NNT, and CI calculated from event rates and hazard ratios in ar...
Source: Annals of Internal Medicine - February 19, 2013 Category: Internal Medicine Authors: Cheung AM Tags: Ann Intern Med Source Type: research
Hypertension in pregnancy is associated with elevated C-reactive protein levels later in life
Objectives:We assessed whether hypertension in pregnancy is associated with elevated C-reactive protein (CRP) levels in later life, possibly reflecting an increased risk of cardiovascular disease (CVD).
Background:Elevated CRP levels have been associated with hypertension in pregnancy and with CVD.
Methods:We studied 2463 women from the Genetic Epidemiology Network of Arteriopathy (GENOA) study. Participants were categorized as nulliparous women (n = 219), women with a history of normotensive pregnancies (n = 1839), or women with a history of a hypertensive pregnancy (n = 405). Using multiple linear regression ...
Source: Journal of Hypertension - October 8, 2013 Category: Cardiology Tags: ORIGINAL PAPERS: Pregnancy Source Type: research
Hormone replacement therapy in menopause
Embora o estrógeno já esteja disponível para venda há mais de seis décadas, as mulheres ainda permanecem confusas quanto ao risco e aos benefícios da terapia hormonal na menopausa (THM), terapia estrogênica isolada ou associada a progestágenos. A publicação de estudos controlados, randomizados, como o Heart and Estrogen/progestin Replacement Study (HERS) e Women’s Health Initiative (WHI), intensificou essa controvérsia risco/benefício. Milhares de mulheres são tratadas com THM para alívio dos sintomas menopausais, incluindo sintomas vasomotores e sudorese, principal indicação da estrogenoterapia. Outras p...
Source: Arquivos Brasileiros de Endocrinologia e Metabologia - May 14, 2014 Category: Endocrinology Source Type: research
Being happy 'won't help you live longer' survey finds
ConclusionThis large prospective study aimed to assess whether happiness or related measures of wellbeing are associated with risk of death, after allowing for the influence of the poor health and lifestyles of people who are unhappy.The study found poor health was linked with unhappiness in middle-aged women. However, after allowing for this association and adjusting for the influence of other factors that may be associated, such as smoking and poor socioeconomic status, happiness and related measures of wellbeing do not appear to have any direct effect on death. This suggests that, as has sometimes previously been specu...
Source: NHS News Feed - December 11, 2015 Category: Consumer Health News Tags: Lifestyle/exercise Mental health Source Type: news
Cardiovascular Programming During and After Diabetic Pregnancy: Role of Placental Dysfunction and IUGR
This study demonstrated that the incidence of ischemic heart disease and death were three times higher among men with low birth weight compared to men with high birth weight (5). Epidemiological investigations of adults born at the time of the Dutch famine between 1944 and 1945 revealed an association between maternal starvation and a low infant birth weight with a high incidence of hypertension and coronary heart disease in these adults (23). Furthermore, Painter et al. reported the incidence of early onset coronary heart disease among persons conceived during the Dutch famine (24). In that regard, Barker's findin...
Source: Frontiers in Endocrinology - April 8, 2019 Category: Endocrinology Source Type: research
How Menopause Affects Cholesterol —And How to Manage It
Kelly Officer, 49, eats a vegan diet and shuns most processed foods. So, after a recent routine blood test revealed that she had high cholesterol, “I was shocked and upset,” she says, “since it never has been [high] in the past.”
Officer is not alone. As women enter menopause, cholestrol levels jump—by an average of 10-15%, or about 10 to 20 milligrams per deciliter. (A healthy adult cholesterol range is 125-200 milligrams per deciliter, according to the National Library of Medicine.)
This change often goes unnoticed amidst physical symptoms and the general busyness of those years. But, says D...
Source: TIME: Health - September 21, 2022 Category: Consumer Health News Authors: Katherine Harmon Courage Tags: Uncategorized freelance healthscienceclimate heart health Source Type: news
Hormone therapy not recommended for chronic disease prevention in menopausal women
Commentary on: Nelson HD, Walker M, Zakher B, et al.. Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the US Preventive Services Task Force recommendations. Ann Intern Med 2012;157:104–13. Context In 2005, the US Preventive Services Task Force (USPSTF) updated its 2002 hormone replacement therapy recommendations, advising against the routine use of oestrogen and progestin (E+P) and unopposed oestrogen (E) to prevent chronic conditions in menopausal women. Menopausal hormone therapy (MHT) had been commonly prescribed to prevent conditions such as cardiovascula...
Source: Evidence-Based Medicine - May 15, 2013 Category: Internal Medicine Authors: Wenger, N. K. Tags: Pancreas and biliary tract, Epidemiologic studies, Drugs: cardiovascular system, Dementia, Stroke, Contraception, Drugs: obstetrics and gynaecology, Menopause (including HRT), Ischaemic heart disease, Venous thromboembolism, Memory disorders (psychiatry), Source Type: research
The Timing Hypothesis and Hormone Replacement Therapy: A Paradigm Shift in the Primary Prevention of Coronary Heart Disease in Women. Part 2: Comparative Risks
A major misperception concerning postmenopausal hormone replacement therapy (HRT) is that the associated risks are large in magnitude and unique to HRT, but over the past 10 years, sufficient data have accumulated so that the magnitude and perspective of risks associated with the primary coronary heart disease prevention therapies of statins, aspirin, and postmenopausal HRT have become more fully defined. Review of randomized controlled trials indicates that the risks of primary prevention therapies and other medications commonly used in women's health are of similar type and magnitude, with the majority of these risks ca...
Source: Journal of the American Geriatrics Society - May 20, 2013 Category: Geriatrics Authors: Howard N. Hodis, Wendy J. Mack Tags: Updates on Aging Source Type: research
Could Antibodies or Hormones Slow Brain Damage from Alzheimer’s?
Scientists have discovered that certain antibodies may help slow the progression of Alzheimer’s disease. Dr. Patricia Salinas of University College London, UK, and her team focused on a protein called Dkk1, present in raised levels in the brains of people with Alzheimer’s disease.
Using brain samples from mice, the team looked at the progressive disintegration of synapses in the hippocampus when exposed to a protein called amyloid-beta, thought to be central to the development of Alzheimer’s disease.
“Synaptic loss mediated by amyloid-beta in early stages of the disease might contribute to cognitive...
Source: Psych Central - June 1, 2013 Category: Psychiatry Authors: Jane Collingwood Tags: Aging Alzheimer's Disorders General Seniors Abnormal Deposits Alzheimer S Disease Antibodies Brain Area Brain Damage Cognitive Decline Cognitive Impairments Disintegration Dr Patricia Dr Simon Hippocampus Journal Of Neurosc Source Type: news
Drugs to be offered to women at high risk of breast cancer
The National Institute of Health and Care Excellence (NICE) has today released updated guidelines on the care of women who are at increased risk of breast cancer due to their family history. One of the main changes to the original guidance from 2004 is that NICE now recommends drug treatment with tamoxifen or raloxifene to reduce risk of breast cancer in a specific group of women who are at high risk of breast cancer and have not had the disease.
They say that these treatments could help prevent breast cancer in about 488,000 women aged 35 years and older.
The updated guideline has also made changes to the recommende...
Source: NHS News Feed - June 25, 2013 Category: Consumer Health News Tags: Cancer Medical practice QA articles Source Type: news
